According to Millennium Research Group's Global Markets for
Atrial Fibrillation (AF) Treatment Devices 2008 report, over 32,000
electrophysiology (EP) procedures were performed for the treatment of AF
in the US in 2007. AF EP procedure volumes will increase at a compound
annual growth rate of over 25% from 2008 to 2012.
Growth in procedure volumes will be driven by the increasing
physician acceptance of EP ablation as a viable and effective treatment
for AF. Over the next several years, these procedures will be used more
often over medical therapy than in the past. The introduction of new
technology will also support greater procedure volumes through 2012;
these new devices will enable physicians to increase the safety,
efficiency, and efficacy of EP ablation catheter procedures. By 2012,
over 109,000 EP procedures will be performed to treat AF in the US.
"The patient pool that hasn't been treated in this market
is huge and growing," said Andrew Wong, Analyst at Millennium
Research Group. "Almost 3 million people have atrial fibrillation
in the US, but currently only about 100,000 are being treated
annually."
The Global Markets for Atrial Fibrillation Treatment Devices 2008
report includes coverage of the AF EP, cardiac rhythm management, and
surgical ablation device markets. This report provides coverage of US,
Europe, and Japan and all key industry competitors, including Biosense
Webster, Boston Scientific, Medtronic, and St. Jude Medical.
About Atrial Fibrillation
AF is a type of cardiac arrhythmia. In AF, the atria of the heart
are stimulated by abnormal electrical impulses from the sinoatrial node
and malfunctioning atrial tissue, resulting in an irregular and
disorganized heart beat. AF can lead to heart failure and has been
recognized as a major risk factor for stroke. Increased age and
unhealthy lifestyle choices are risk factors in developing AF.
About Millennium Research Group
Millennium Research Group, a Decision Resources, Inc. company
(http://www.DecisionResources.com), is the global authority on medical
technology market intelligence and a leading provider of strategic
information to the health care sector. Focused solely on the medical
device, pharmaceutical, and biotechnology industries, the company
provides its clients with the benefits of its specialized industry
expertise through published reports and customized consulting services.
For more information, call 416/364-7776, ext. 101 or visit
http://www.mrg.net.
COPYRIGHT 2008 Worldwide
Videotex Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
Copyright 2008 Gale, Cengage Learning. All rights
reserved. Gale Group is a Thomson Corporation Company.
NOTE: All illustrations and photos have been removed from this article.